EPISODE · Nov 8, 2025 · 11 MIN
Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs
from BiotechTV - News · host BiotechTV
The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.
What this episode covers
The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.
NOW PLAYING
Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m